Cytokinetics drug hits dual goals in genetic heart disease study

Adam Feuerstein is a senior author and biotech columnist, reporting on the crossroads of drug improvement, enterprise, Wall Street, and biotechnology. He can also be a co-host of the weekly biotech podcast The Readout Loud and creator of the e-newsletter Adam’s Biotech Scorecard. You can attain Adam on Signal at stataf.54.

Cytokinetics stated Tuesday that its drug Myqorzo considerably improved heart failure signs and cardiovascular health in sufferers with non-obstructive hypertrophic cardiomyopathy, an inherited heart dysfunction.

The outcomes, reported in an organization press launch, achieved the dual efficacy goals of a Phase 3 medical trial, referred to as ACACIA, with statistical significance.

Cytokinetics is in the early days of Myqorzo’s industrial launch as a therapy for the extra extreme “obstructive” type of hypertrophic cardiomyopathy, or HCM. The profitable end result of the ACACIA study, if additionally cleared by regulators, might enormously develop the variety of HCM sufferers eligible for therapy — and improve the drug’s peak gross sales to $5 billion yearly, in keeping with analyst forecasts.

STAT+ Exclusive Story

Already have an account? Login

This article is unique to STAT+ subscribers

Unlock this text — plus each day protection and evaluation of the biotech sector — by subscribing to STAT+.

Already have an account? Login

Individual plans

Group plans

View All Plans